Diarrhea News and Research

Latest Diarrhea News and Research

Gluten-free diet more of a fad than absolute necessity for many

Many people claim that gluten sensitivity is on the rise and consequently gluten-free products are more popular than ever. A study explores whether shunning gluten is really necessary and finds that in most cases it is not.

22 Feb 2012

Norovirus outbreak at the George Washington University campus

Officials at the university and the District of Columbia's Health Department confirmed 85 cases of the gastrointestinal illness were diagnosed since Monday. The virus was found in locations including the central Foggy Bottom campus and the Mount Vernon campus in Northwest Washington. Members of the university also reported cases off campus.

18 Feb 2012

MSF warns health, living conditions of refugees in Dadaab camp deteriorating

The medical aid group Medecins Sans Frontieres (MSF) on Thursday said the conditions for hundreds of thousands of refugees living in Kenya's Dadaab refugee camp are worsening and people there "are experiencing a 'humanitarian emergency' because of the scaling back of aid work," Deutsche Presse-Agentur/M&C reports (2/16).

18 Feb 2012

Increased bacterial loads in potable water may have significant health effects on indigenous people

Indigenous people around the world are among the most vulnerable to climate change and are increasingly susceptible to the pathogen loads found in potable water after heavy rainfall or rapid snow melt.

18 Feb 2012

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.

17 Feb 2012

First accurate predictive model to differentiate between dengue fever and dengue hemorrhagic fever

Researchers at the University of Texas Medical Branch have developed the first accurate predictive model to differentiate between dengue fever (DF) and its more severe form, dengue hemorrhagic fever (DHF).

17 Feb 2012

U.S. FDA accepts Pfizer's tafamidis NDA for treatment of TTR-FAP

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tafamidis meglumine, the company's investigational, novel, oral therapy for the treatment of Transthyretin Familial Amyloid Polyneuropathy.

16 Feb 2012

Study: Diabetes may begin in the gut

Scientists at Washington University School of Medicine in St. Louis have made a surprising discovery about the origin of diabetes. Their research suggests that problems controlling blood sugar - the hallmark of diabetes - may begin in the intestines.

15 Feb 2012

Water-associated disease outbreaks more likely to occur in high population density areas

Water-associated infectious disease outbreaks are more likely to occur in areas where a region's population density is growing, according to a new global analysis of economic and environmental conditions that influence the risk for these outbreaks.

15 Feb 2012

Kowa announces data of LIVALO vs. Crestor on pharmacodynamics of warfarin

Kowa Pharmaceuticals America, Inc. today announced data assessing the effect of LIVALO (pitavastatin) compared with Crestor (rosuvastatin) on steady-state pharmacodynamics (PD) of warfarin by measuring international normalized ratio (INR) in healthy adult subjects.

14 Feb 2012

IBD may disrupt school functioning in children

Children with inflammatory bowel disease (IBD) may have difficulty functioning in school, particularly because their tendency to internalize problems can impact attendance.

14 Feb 2012

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the fourth quarter and full year 2011 and provided an update on development programs.

13 Feb 2012

Santarus initiates enrollment in UCERIS Phase IIIb study for ulcerative colitis

Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.

13 Feb 2012

Preliminary results from Soligenix SGX201 Phase 1/2 trial on acute radiation enteritis

Soligenix, Inc., a development stage biopharmaceutical company, announced preliminary results today from a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

10 Feb 2012

Acid reducing drugs could raise risk of C. diff diarrhea

U.S. health regulators, the Food and Drugs Administration (FDA), have announced that ulcer drugs such as AstraZeneca Plc's blockbuster Nexium could increase the risk of Clostridium difficile-associated diarrhea (CDAD).

9 Feb 2012

Now on stands - Inhaled caffeine

A Harvard professor has come up with a device that helps people inhale their caffeine from a lipstick-sized tube. Critics say the novel product, called “AeroShot,” is not without its risks. The product went on the market late last month in Massachusetts and New York, and is also available in France. A single unit costs $2.99 at convenience, mom-and-pop, liquor and online stores.

9 Feb 2012

Genzyme announces four-year data from eliglustat tartrate phase 2 trial on Gaucher disease type 1

Genzyme, a Sanofi company, announced today four-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate.

8 Feb 2012

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application for pertuzumab and granted Priority Review.

8 Feb 2012

Whole-genome sequencing helps trace the path of European E. coli outbreak

Using whole-genome sequencing, a team led by researchers from Harvard School of Public Health (HSPH) and the Broad Institute has traced the path of the E. coli outbreak that sickened thousands and killed over 50 people in Germany in summer 2011 and also caused a smaller outbreak in France.

7 Feb 2012